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The lack of effective treatment against hepatocellular carcinoma (HCC), 
the fifth most common malignancy and the third leading cause of cancer deaths 
worldwide calls for direct efforts to better understand the disease and identify new 
drug targets. In the search for novel multi-kinase inhibitors to treat this disease, our 
group found a very potent compound which acts on a relatively uncharacterized 
receptor tyrosine kinase, Tyro3. To explore the potential role of tyrosine kinase Tyro3 
in HCC, we examined the expression of Tyro3 in HCC tumors and correlated it with 
clinical outcomes. Using cDNAs derived from 56 HCC patients and quantitative RT-
PCR (qRT-PCR) analysis of Tyro3, we found frequent and significant overexpression 
which also corresponded to elevation of clinico-pathological markers for HCC such as 
hepatitis B virus (HBV) infection, α-fetoprotein (AFP), aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) levels. To determine the cause-and-effect 
relationship between Tyro3 expression and these HCC phenotypes, we performed in 
vitro investigation using siRNA silencing of Tyro3 in a high expressing HCC cell line, 
Hep3B and found it to suppress cell proliferation. From these efforts, we have 
gathered important basis for further work to characterize Tyro3 as a potential and 
novel drug target in HCC. Of equal importance, we have successfully developed 
useful and relevant in vitro models that will support subsequent effort to understand 
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1. 1 Introduction to HCC 
 
 Primary liver cancer is the fifth most common cancer type worldwide. 
Among which, hepatocellular carcinoma (HCC) contributes about 85-90% of all cases 
[1]. In 2008, there were about 696,000 deaths, making this the 3rd largest cause of 
cancer death and hence a major healthcare burden [2]. While the disease inflicts 
people of all ethnicities, people in Asian countries are reported to have higher 
incidence of HCC than the Western countries [3]. Furthermore, gender difference 
exists significantly whereby males represent higher risk of developing HCC than 
females, especially for patients who are older than 50 years old. The ratio of male to 
female for HCC ranges from 2:1 to 4:1[1]. For this reason, HCC is the 4th most 
frequently occurring cancer in male and ranks much lower for the female gender [2]. 
The exact mechanism for such differences is not clear but it was suggested that the 
differential expression of androgen receptors may correlate with this gender disparity 
[4]. HCC also exhibits age disparity whereby risk and manifestation increase 
significantly with age. For example, after liver transplantation, the immune response 
for older people is likely to be much higher than younger patients. These observations 
may also underline the prolonged incubation period before disease manifestation. 






1.2 Etiology of HCC 
 
Like several other malignancies, HCC is a disease with multiple causes. 
To date the main causes that have been identified include chronic alcohol abuse, 
hepatitis C infection (HCV), hepatitis B infection (HBV), and exposure to chemical 
carcinogens (such as Aflatoxins and vinyl chloride). There is also significant 
geographical disparity in terms of the etiology of HCC. In US, HCV infection is the 
predominant cause of HCC, whereas in China, HBV is most prevalent. Together, 
HBV and HCV account for 80%-90% of all HCC incidences worldwide [3]. Both 
diseases are chronic infection of the liver and carriers of these viruses can remain 
asymptomatic for 30-50 years before some of them progress into HCC. Effective 
vaccination program for HBV started in the 1980s and such measures are believed to 
tremendously reduce the incidence of HCC in time to come [1]. However, for chronic 
HBV and HCV carriers who were already infected prior to vaccination program, their 
risk profile remains high and hence, it is speculated that this disease will continue to 
be a healthcare menace for many more years to come. 
Chronic alcohol abuse can lead to alcoholic liver formation, which also 
predisposes the individual to HCC. Alcohol is metabolized to acetaldehyde by alcohol 
dehydrogenase (ADH) and subsequently to acetic acid by acetaldehyde 
dehydrogenase (ALDH). Acetaldehyde is a known chemical carcinogen that can react 
with proteins/nucleic acids as a result of its electrophilicity. In this context, persistent 
exposure to acetaldehyde due to chronic alcoholism or failure in metabolism can 
result in a liver-directed injury that often begins with fatty liver (steatosis) and liver 
fibrosis. Unresolved cirrhosis will then predispose the individual to the more 
detrimental consequences of hepatocarcinogenesis [5, 6].   
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Another major contributor of HCC arises from Aflatoxin B1 (AFB1) 
exposure. AFB1 is a mycotoxin produced by Aspergillus flavus. This fungus thrives in 
warm and moist environment and populates in crops such as peanuts, corns and maize 
etc. When ingested as part of the contaminated food product, AFB1 is metabolized by 
Cytochrome P450 enzymes via oxidation to generate reactive epoxides that 
subsequent bind and modify DNA [7]. AFB1 has in fact been shown to be one of the 
most potent carcinogens known to date. Today, AFB1 is a major contributor to HCC 
particularly in Southern China and the Sub-Saharan continent where moist and humid 




Regardless of the source of the initial lesion in the liver (i.e. HBV, HCV 
infection, alcoholic liver injury, aflatoxin etc), some common processes in 
hepatocarcinogenesis emerge. The understanding of this process is pertinent to the 
development of effective strategies to cope with the problem. The disease usually 
follows a progression from a prolonged inflammatory state to eventually, tumorigenic 
development and progression. With persistent exposure to agents that cause liver 
inflammation, the injured liver activates compensatory responses that attempt to 
resolve the injury. This process involves the activation of hepatic stellate cells which 
increases the deposition of extracellular matrix such as collagen (fibrogenesis) [8]. 
This leads to an increase in scar tissue formation that compromises overall liver 
function. As the fibrotic condition aggravates, further reduction in hepatocellular 
function results in a liver cirrhotic state. Cirrhosis is a state of liver when liver tissue 
becomes more rigid, so that the normal function of liver such as detoxifying, 
glycogenesis and synthesis of clotting factors was decimated. This process can take 
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place over several years of incubation period.  On average, it takes about 25-30 years 
to develop HCC after initial HCV exposure [1]. A similar hepatocarcinogenesis 
process was also reported for HBV infection. 
The role of cirrhosis to HCC is especially critical as most HCC arise 
from cirrhosis as a pre-neoplastic event. Cirrhosis was described to accelerate 
hepatocarcinogenesis through various mechanisms. With chronic liver inflammation, 
hepatocytes reach their limits in regeneration due to the shortening of telomeres. This 
state of senescence will induce DNA damage leading to chromosomal instability [9]. 
Secondly, cirrhosis is also known to change the liver microenvironment due to the 
deposition of an altered extracellular matrix and increase oxidative stress that 
promotes tumor proliferation [10]. That said, there are yet patients with HBV 
infection who may directly develop HCC after a period of HCC infection without 
cirrhosis as a pre-neoplastic event [11]. The exact mechanistic details for the disease 
development await further investigation. 
 
1.4 Current treatments for HCC 
 
Today, treatment for HCC is suboptimal with 1-year and 3-year survival 
at approximately 20% and 5% respectively, and a median survival of only 8 months 
[12]. Most of the available treatment modalities are non-curative. Liver 
transplantation is the only curative approach. However, this option is only available 
for a small subset of patients who are presented with isolated and limited vascular 
invasion [13]. Moreover, the number of patients awaiting transplant far exceeds that 
of the number of genetically matching donors, hence transplantation is not a viable 
option for most patients. Post-transplantation, there is also a risk of organ rejection 
which reduces long term survival. Additionally, overall survival and disease-free 
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survival are also compromised by the presence of macroscopic vascular invasion and 
satellite nodules. Immune response also tends to be relatively high after liver 
transplantation. The 15-year survival is 58% in patients who undergo liver 
transplantation [14]. 
Besides complete liver transplantation, partial liver resection could help 
another subset of patients with isolated tumors and sufficient liver function. Together 
with transplantation, surgical resection may give an optimistic 5-year survival at about 
5-60% [13]. Likewise, this option is not suited for the many patients who are first 
diagnosed at an advanced stage where intrahepatic metastasis has already occurred. 
Short of this option, other available treatments for HCC now include locoregional 
therapies such as ethanol injection, radiofrequency ablation, and transarterial 
chemoembolization (TACE). Also, there is a place for conventional chemotherapy 
and more recently, molecular targeted drug therapies are introduced but they are 
mostly in the experimental phase [12]. Ethanol injection is suitable for small and 
single tumors, but the average survival rate is relatively low [15]. Radiofrequency 
ablation is also used to treat HCC, especially in combination with hepatic resection. 
But it also suffers from some limitations such as biliary tract damage, liver failure and 
local recurrence [16]. 
Systemic chemotherapy has limited role in HCC as it is often left as a 
final line of action. At this stage, patients are almost resistant to available 
conventional chemotherapy, even though some other malignancies may have 
responded more positively to such treatments. Furthermore, these agents suffer from 
common side effects due to non-targeted cytotoxicities on rapidly dividing cells such 
as hair loss, fatigue and immunosuppression. For example, doxorubicin and cisplatin 
are both used systemically as chemotherapeutic agents to treat HCC but neither 
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showed significant survival advantage. Overall survival was further reduced for 
patients with high HBV DNA load [17]. An additional challenge comes from the fact 
that HCC is often manifested as a dual disease of both cancer and liver dysfunction 
due to the underlying cirrhosis. Hence, many pharmacological interventions 
(particularly those that are extensively metabolized by the liver) will experience 
abnormal pharmacokinetics that requires specialized care and monitoring. Clearly, 
there are several limitations for existing treatment for hepatocellular carcinoma. 
Therefore, this generates a dire need for new methods for HCC treatment that could 
benefit more patients, reduce immune response and prolong patients’ survival rate and 
survival time   
  
1.5 New drugs for HCC treatment 
 
In view of these challenges, newer molecular targeted therapies that 
recently emerged in the market for other malignancies are being explored for HCC 
[18]. Molecular targeted therapy is a revolutionary approach to cancer treatment by 
targeting the underlying mechanism that drives the cancer phenotypes. These 
phenotypes can include that of hyperproliferation, anti-apoptosis, cellular 
transformation, angiogenesis and even inflammation [19]. It is believed that every 
cancer arises from some cell signaling aberrations that may be different from one 
cancer to another. Therefore, it is possible to identify such aberrations and block them 
selectively so that the effect on adjacent normal cells will be minimized. This 
overcomes the challenge of cytotoxicities on other hyperproliferating normal tissues 
on which conventional chemotherapy tends to exert. Furthermore, the specific 
inhibition of cancer phenotypes can also lead to a more wholesome resolution of the 
disease, besides just eliminating the rapidly dividing cancer cell population. For 
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example, bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) 
monoclonal antibody that binds and neutralizes human VEGF,   was approved in 2004 
for first-line treatment of metastatic colorectal cancer patients in combination with 5-
fluorouracil-based chemotherapy [20]. VEGF is an important growth factor that binds 
and activates vascular endothelial growth factor receptor (VEGFR), which is found to 
be overexpressed in several colorectal carcinomas to support neo-angiogenesis and 
the growth of the tumor. Hence, its inhibition is aimed to block new blood vessels to 
deprive the tumor of the necessary nutrients to support further spreading of the 
cancerous growth. Gefitinib can target the epidermal growth factor receptor (EGFR) 
tyrosine kinase and is approved in the U.S. for non small cell lung cancer. Several 
non-small cell lung carcinomas (NSCLC) carry activating mutation of EGFR which 
results in constitutively active signaling of downstream extracellular signal-regulated 
kinase (ERK) signaling to support cancer cell proliferation [21]. Hence, this agent 
specifically corrects the aberration only in the cancer tissue that manifests this genetic 
lesion. 
Sorafenib is a drug approved by the Food and Drug Administration 
(FDA) in year 2007 for HCC treatment. It is also used for the treatment of renal cell 
carcinoma. This agent became the very first molecular target therapy that opened new 
possibilities for the treatment of HCC. In the hallmark paper leading to its approval, 
an international phase III, placebo-controlled study showed that sorafenib 
significantly improved overall survival (median overall survival 10.7 months with 
sorafenib vs. 7.9 months with placebo) [22]. In a follow-up clinical trials focusing on 
Asian population, the median overall survival for the sorafenib arm is 6.5 months vs. 
4.2 months for placebo [23]. The mechanism underlying sorafenib treatment is that 
this tyrosine kinase inhibitor is able to block several signaling pathways, resulting in 
8 
 
repression of cell proliferation [24]. Sorafenib was originally developed as a RAF 
kinase inhibitor which then blocks ERK signaling pathway and alters some 
phenotypes of liver cancer cell lines. More recently, sorafenib was shown to exhibit 
multi-targeting effect and exert inhibitory effect on some tyrosine kinases. The 
regulation of angiogenesis is a complex, multistep process resulting from a dynamic 
balance between pro-angiogenic and anti-angiogenic factors. Two of the most 
important regulators of this process are the VEGF and platelet-derived growth factor 
receptor (PDGFR) [25]. It was subsequently evaluated that these tyrosine kinase 
targets could turn out to be more critical for its efficacy as anti-cancer agent, 
particularly in metastatic tumor.  
The unprecedented success of sorafenib turned the page on 
pharmacotherapy against HCC as it triggered further investigation into other tyrosine 
kinase inhibitors in the treatment of HCC. The benefit of this approach is believed 
that tyrosine kinase inhibitors can target those tyrosine kinases that are important in 
the initiation and progression of HCC. This is an emerging field as more and more 
tyrosine kinases are being identified to be implicated in HCC. 
 
1.6 Tyrosine kinases implicated in HCC  
 
Therefore, a successful application of tyrosine kinase inhibitors requires 
a clear understanding of their involvement in the target disease. Generally, aberrant 
signaling of tyrosine kinases are mediated by increased activity either mediated by 
increased binding of growth factors, overexpression of the receptors, or mutation of 
the receptor or their downstream signaling targets to result in elevated cellular 
activities and responses. For receptor tyrosine kinases, they are usually activated by 
first binding to specific ligands (usually growth factors). This results in 
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conformational change which allows the dimerization of the receptor and the 
activation of the intracellular kinase domain. The innate kinase activity results in 
transphosphorylation of the receptor itself or other kinase targets which generates 
anchoring sites for other cell signaling molecules that subsequently activate a cascade 
of pathways resulting in cancer-like behaviors. Many of their signaling converge onto 
pathways such as phosphoinositide 3-kinase (PI3K) and ERK signaling which are 
important in mediating cell cycling, proliferation, cell invasion, and metastatic 
behavior, apoptosis as well as other cell phenotypes which attribute partially to their 
suitability as anti-cancer targets [26, 27]. 
For instance, activation of EGFR and type1 insulin-like growth factor 
receptor (IGF1R) tyrosine kinases mediate the activation of PI3K [28, 29]. This in 
turn will elevate Akt phosphorylation which is then responsible for inhibiting 
mitochondrial anti-apoptotic mechanism through BAD and BCL-xL, as well as mTOR, 
which promotes cell proliferation. The mammalian target of rapamicin mammalian 
target of rapamycin (mTOR) pathway is implicated widely in cancer pathophysiology. 
Dual inhibition of the mTOR kinase complexes, mammalian target of rapamycin 
complex 1 (mTORC1) and mammalian target of rapamycin complex 2 (mTORC2) 
decreases tumor xenograft growth in vivo [30]. Separately, ERK/mitogen-activated 
protein kinase (MAPK) pathway is another key regulator of cancer phenotypes such 
as proliferation, differentiation and even angiogenesis. When growth factors bind to 
various receptors such as EGFR, phosphorylation will trigger the association of 
adaptor molecules which in turn activate RAS/RAF/ERK signaling [31]. Therefore, 
the use of tyrosine kinase inhibitors such as gefitinib (EGFR inhibitor), was expected 
and have been shown to suppress some of these phenotypes [32]. 
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With the essential role of the tyrosine kinases in cancer, another key that 
makes them suitable drug targets is their position in the top echelon of cellular 
signaling, as they generally bind to extracellular signaling molecules at their receptors 
and transmit this information intracellularly. Therefore, they are conveniently located 
for the binding of small molecules (<500 Daltons), and hence, highly druggable 
targets to consider for cancer therapeutics. Their popularity in pharmaceutical 
research and development (R&D) is further stimulated by early discoveries that 
several tyrosine kinases have already been reported to have implication on HCC 
development of which a few key examples will be discussed in the following 
paragraphs. 
IGF-1R is one of the first tyrosine kinase found to be associated with 
liver cancer. An increase in the ligand, Insulin-like growth factor 2 (IGF-2), as well as 
the receptor, was found in cirrhosis as well as in HCC. Many biochemical studies 
have characterized the role of IGF-IR in hepatocarcinogenesis and its control over 
downstream cell cycling and anti-apoptotic pathways in HCC models [33, 34]. Within 
the last decade, efforts at developing targeted inhibitors have also demonstrated 
promising results on HCC. In 2006, a small molecule inhibitor, NVP-AEW541 was 
able to suppress growth and cell cycling in HCC cell line [35]. Other molecules as 
well as therapeutic monoclonal antibodies are now in various stages of pre-clinical 
and clinical development.  
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that was 
shown to be upregulated in HCC. In a recent study, FAK, together with a microRNA-
151, were found to act synergistically to enhance cell motility and spreading in HCC. 
This controls the rate and extent of intra-hepatic metastasis of HCC, a major cause of 
mortality for the disease [36]. Separately, FAK activation has also been linked to 
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HBV gene product, HBx, and hence may be able pivotal point for pharmacological 
intervention against HBV-infected HCC [37]. 
Fibroblast growth factor receptor 4 (FGFR4) is constitutively and highly 
expressed in liver, hence suggesting its physiological function in the liver such as bile 
acid synthesis. Therefore, it is conceivable that perturbation of its signaling may result 
in pathological consequences. Recently, our group has found that approximately one-
third of HCC patients demonstrated an elevation of FGFR4 in the tumor as compared 
to the adjacent normal tissue. Furthermore, there is an association between a 
frequently-occurring polymorphism, FGFR4-G388R, and an increased AFP levels in 
such patients. Inhibition of FGFR4 via both small molecule inhibitor and siRNA 
approaches suppressed cell proliferation and AFP production in HCC cell lines. These 
findings support the role of FGFR4 in HCC progression of which further investigation 
is underway [38].  
Beside these, there are several other tyrosine kinases found to be 
modulated either by overexpression, or the acquisition of germ-line or somatic 
mutations in HCC. Theses associations prompted mechanistic work to establish 
causality as well as to investigate their potential as drug targets. Some additional 
examples include MET, PYK and many others. Table 1 below summarizes the 
tyrosine kinases that have been reported to be linked to HCC based on current 
literatures.  
Table 1 Tyrosine kinases that have been implicated in HCC 
Gene Description References 
AXL Preferentially expressed in HCC by parallel hybridization [39, 40] 
EphA1 Silencing of EphA1 exhibits anti-angiogenic and anti-tumor effect in HCC [41] 
EphB2 Upregulated 9-fold in HCC [42] 
FAK 
mRNA expression correlated with tumor size, AFP, disease 





FGFR3 Associated with poor tumor differentiation and increased nuclear grade [44] 
FGFR4 Preferentially expressed in HCC by parallel hybridization [38, 39] 
HER 2 Increased expression and association with HBx [45] 
HER3 Elevated HER3 and cognate partners by microarray; Associated with disease progression [46, 47] 
IGF-1R Critical for malignant transformation in HCC [33, 48] 
JAK1 HBx activates JAK1 through direct protein interaction [49] 
JAK3 Higher basal level detected in HepG2 [50] 
Kit Expression in oval cells of most HCC of HBV-origin [51-53] 
MET 
Mutations associated with accelerated carcinogenesis in 
childhood HCC: T1191I, K1262R, M1268I; Met silencing 
inhibited HCC growth in vivo 
[54, 55] 
PDGFR-α Overexpression in vascular endothelium of highly metastatic HCC [56] 
PDGFR-β Preferentially expressed in HCC by parallel hybridization [39] 
Pyk2 Contributes to tumor metastasis [57, 58] 
RON Unregulated RON and MET expression associated with HCC [59] 
Src Activation of Src in early HCC [60] 
TIE2 
Overexpressed in neovascular endothelium of most HCC. 
More recently, Ang-1 and -2 are also shown to be 
upregulated 
[61] 
VEGFR1/2 Upregulated in EC of HCC [62] 
VEGFR3 
Overexpression of VEGFR3-short after HBx stable 
transfection in HepG2 cells. VEGFR3-s correlate with 
survival in patients 
[63] 
This table is a compilation of tyrosine kinases reported to be associated in HCC 
based on a data-mining of literatures catalogued by PubMed (National Center for 
Biotechnology Information, NIH, USA). The reported genes are listed alphabetically 
and their corresponding references are cited. 
 
Some tyrosine kinases inhibitors are already in various stages of clinical 
trials for HCC. For example, erlotinib and gefitinib, both EGFR inhibitors are in 
phase II or phase III clinical trials. Lapatinib, that target Her-2/neu, is now in phase II 
or phase III clinical trials. Sunitinib, another multi-kinase targeting inhibitor like 
sorafenib was also tested in HCC studies. Table 2 summarizes some of the ongoing 
trials involving tyrosine kinases. Currently, these clinical trials yielded mixed results. 
In an open-label phase II clinical study on sunitinib conducted on 37 patients, 
sunitinib showed severe hematological side effects and only one patient showed 
partial response [64]. Another phase II study on brivanib, an fibroblast growth factor 
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receptor 1 (FGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) 
inhibitor, with 55 unresectable metastatic tumors, revealed that almost half of the 
patients achieved stable disease or response (i.e. complete or partial response)  with 
little use-limiting toxicities [65]. Several other clinical trials for various agents 
displayed only marginal responses [66, 67]. Clearly, more effort is required to 
understand the specific roles of different tyrosine kinases in HCC in order to better 
treat the disease using such pharmacological agents.  
 
Table 2 Tyrosine kinase inhibitors in clinical trials for HCC treatment 
Drug Sponsor Targets Country Phase 
Sorafenib* Bayer VEGFR, PDGFR, Kit, Flt3 Multi-national Approved 
Gefitinib Multiple EGFR Multi-national II 
Sunitinib Multiple VEGFR, PDGFR, Kit, Flt3 Multi-national II 
Bevacizumab/Erlotinib Multiple EFGR US II 
Fostamatinib NCI Syk US II 
Dasatinib NCI Bcr-Abl, Src US I/II 
TSU-68 Taiho VEGFR, FGFR, PDGFR Japan I/II 
Pazopanib GSK VEGFR, PDGFR, c-kit Multi-national I 
Lapatinib NCI EGFR, HER2 US II 
ABT-869 Abbott VEGFR, PDGFR Multi-national II 
Brivanib BMS VEGFR2, FGFR1 Multi-national II/III 
Cediranib AstraZeneca VEGFRs US I/II 
Dovitinib Novartis FGFR/VEGFR/ PDGFR Multi-national II 
Foretinib GSK MET/VEGFR Asia I/II 
This table summarizes the various tyrosine kinase inhibitors clinical trials that are 
ongoing or completed for HCC. The data is obtained by mining the information from 




One of the subfamily of tyrosine kinases of growing interest to cancer 
research is the TAM receptor family. There are three members in TAM family, 
including Tyro3, Axl and Mer. Axl is the most well studied member in this family and 
has been found to be involved in many cancer types, including HCC [39]. It was 
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indicated that AXL is a mediator of Yes-associated Protein (YAP)-dependent 
oncogenic activities and implicates it as a potential therapeutic target for HCC [40]. In 
renal cancer cell lines, knockdown of Axl could influence cell phenotypes such as cell 
viability, apoptosis, etc. Meanwhile, expression changes of Axl could also influence 
cell cycle, such as prolonging G0/G1 period [69]. Separately, the other family 
member, Mer has been found to play roles in neuronal development [70]. The TAM 
receptor family exhibit significant sequence and structural similarities. For example, 
they all possess two extracellular Immunoglobulin domains, two fibronectin-III 
(FNIII) domains and one intracellular kinase domain. The extracellular segment 
embodies a receptor site for the binding of ligands to initiate the kinase signaling 
cascade. Protein S and Gas6 are specific ligands with high affinity for Tyro3, Axl and 
Mer. By binding to Protein S or Gas6, the TAM family members undergo 
dimerization, phosphorylation and/or glycosylation, which will then be transmitted as 
an intracellular signal for the activation of downstream cellular signaling.    
 
Figure 1 Domain organization of Tyro3, Axl and Mer 
 
TAM family consists of two extracellular immunoglobulin-like domains, 
two Fibronectin III domains, a single-pass transmembrane (TM) region, and one 
intracellular kinase domain [70].  
Tyro3 is the least characterized member in the TAM family. Its 
complete sequence was first reported in 1993 [71]. In 1995, it potential role as an 
oncogene was first characterized by Nobel laureate Prof Harold Varmus. His group 
demonstrated the overexpression of Tyro3 in mammary tumors in rodents and the 
consequence of ligand-independent activation [72, 73]. Tyro3 is also named as Sky, 
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Rse and DTK. To date, Tyro3 has been found to play roles in melanoma and lung 
carcinoma based on its upregulation in these malignancies [74, 75]. However, the 
mechanism for its involvement is still under investigation. 
The downstream of Tyro3 activation has been investigated in some 
studies, but it is still poorly understood. A number of proteins that potentially interact 
with Tyro3 were identified, including p85 β-subunit of PI3K, protein phosphatase 
1(PP1), and RanBPM [76, 77]. It was demonstrated that ligand stimulation of an 
EGFR/Tyro3 chimera induces phosphorylation of Tyro3 and an activation of PI3K, 
and Akt, which resulted in a transformed phenotype. In NIH3T3 cells which express 
endogenous Tyro3, phosphorylation of ERK1/2 was increased by Gas6 stimulation 
[78]. Gas6 stimulation also upregulated the phosphorylation of ERK1/2 in mouse 
osteoclasts, which resulted in bone resorption [79]. Co-immunoprecipitation of Tyro3 
transiently expressed in COS cells revealed a potential interaction with a 
phosphorylated SFK, but it remains unknown which SFK(s) (Src, Yes, and/or Fyn) 
interact with Tyro3 [80]. Many downstream effector genes of these pathways remain 
elusive, and see is to full complement of the biological effect mediated by Tyro3. As 
further efforts are needed to clarify these mechanistic details, the available 
information will serve as useful starting points for us to explore the subcellular 
changes upon perturbation of Tyro3 in HCC models. 
 





Currently, Tyro3 signaling pathways mediate platelet aggregation, cell 
transformation, and osteoclastic bone resorption. The signaling molecules indicated in 
Figure 2 have been shown to associate with Tyro3 through either a direct or indirect 
interaction. Phosphorylation of Tyro3 at specific residues and their biological 





2.0 HYPOTHESIS AND OBJECTIVES  
Hepatocellular carcinoma (HCC) is the third leading cause of cancer 
death worldwide.  
Yet, the understanding of its disease progression and options for 
treatment is still quite limited. Therefore, studying the mechanism underlying HCC 
development and progression is of great importance to establish new and better 
treatments for HCC that will benefit millions of HCC patients in the world [81]. In 
2007, the newly approved tyrosine kinase inhibitor sorafenib represents a big 
breakthrough in HCC treatment. The unprecedented success of this drug supports 
identifying new tyrosine kinases as potential drug targets to help discover more 
molecular targeted inhibitors for HCC treatment. As there is limited number of 
tyrosine kinases reported to be involved in HCC development, we envision that there 
may still be a number of some tyrosine kinases that have not been extensively studied 
in this context. Preliminary results established within our group (unpublished data) 
suggested that Tyro3 could be one of these tyrosine kinases as we found Tyro3 
phosphorylation to be significantly inhibited and resulted in the alteration of HCC 
phenotype in cell culture model systems. Furthermore, silencing of Tyro3 in the same 
cell culture model resulted in a reduced sensitivity for the cells towards the inhibitor. 
Hence, the finding suggests Tyro3 signaling may be critical in the effect of the 
inhibitor, and thereby a target worth investigating with greater depth. Tyro3 belongs 
to TAM (which also include AXL and MER tyrosine kinases) family, which has been 
found to play role in melanoma and hematological tumors [75, 82]. We speculate that 
Tyro3 may play important roles in other cancer types which may even include HCC. 
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As Tyro3 has not been characterized in HCC development before, it is meaningful to 
investigate its oncogenic potential using carefully designed models using of both in 
vitro and in vivo systems.    
Therefore, the over-riding hypothesis of this research work is that the 
tyrosine kinase Tyro3 can play important roles in HCC progression such as cell 
viability. Elevated Tyro3 expression in the tumor versus adjacent normal tissue will 
have significant correlation with clinical data of HCC patients. These in vivo findings 
will shape subsequent in vitro validation work to establish detailed mechanism for its 
effect on HCC. 
To test this hypothesis, the following aims have been crafted: 
1. To determine the expression of Tyro3 in patient samples by RT-PCR, in order 
to find whether Tyro3 is overexpressed in HCC patients, through comparing 
the expression of Tyro3 in tumor tissues with its expression in normal tissues. 
2. To investigate the correlation between Tyro3 expression and patient clinico-
pathological parameters such as AFP level, AST level, age, gender, etiology, 
survival time, tumor size and multiplicity, etc.  
3. To compare the expression of Tyro3 in different HCC cell lines by RT-PCR in 
order to develop a suitable Tyro3-silencing system for subsequent mechanistic 
investigations. 









3.0 MATERIALS AND METHODS 
3.1 Cell Culture 
 
Hep3B cell line was obtained from American Type Culture Collection 
(ATCC) (Manassas, VA, USA). Hep3B was maintained in Minimal Essential 
Medium (MEM) medium supplemented with 10% fetal bovine serum (FBS), sodium 
pyruvate (1 mM) and non-essential amino acids (100X). Cells were passaged every 4-
5 days when they have reached 70% confluency in tissue culture dishes. To passage 
cells, medium in the dish was aspirated and 5 ml of pre-warmed phosphate-buffered 
saline (PBS) was added into the dish to rinse and wash the cells, and then the PBS 
was removed and 5 ml of 0.5% trypsin was added into the dish, incubated at 37 ºC for 
about 5 min. When the cells became round and detached from each other, trypsin was 
removed and cells were washed out with 5 ml of medium to inactivate the trypsin. 
The suspended cells were collected by centrifuging for 3 min at the speed of around 
1,000 rpm. After which, cells were resuspended in appropriate volumes for 
subsequent seeding into new tissue culture dishes for experiments or cell maintenance. 
Cells were maintained at 37 °C in 5% CO2. Unless stated otherwise, all cell culture 
reagents were obtained from Invitrogen (Life Technologies, Grand Island, NY). 
Huh7, HepG2 and SK-Hep1 were also cultured to compare Tyro3 
expression in different cell lines at the translational level. These cell lines were kind 
gifts from Prof Axel Ullrich’s lab at Max-Planck Institute for Biochemistry, 
Martinsried, Germany. The medium used to culture Huh7 was DMEM with 10% 
serum, containing 1mM sodium pyruvate; and that for HepG2 and Sk-Hep1 was 
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MEM with 10% serum, 100x Non-essential Amino Acids (NEAA) and 1 mM sodium 
pyruvate.   
 
3.2 HCC sample preparation 
 
Total RNA was isolated from paired normal and HCC liver tissues from 
HCC patients (n=57) at the National University Hospital (Singapore) as previously 
described. These samples were obtained through collaborating with Prof Lim Seng 
Gee and complete with appropriate approval from the Institutional Review Board 
from the NUH. cDNAs were synthesized from 2 µg RNA using Superscript III 
reverse transcriptase kit (Invitrogen, Singapore), performed according to 
manufacturer’s instructions and as briefly described in a later section.    
 
3.3 Harvesting cells 
 
After cell culture, the cells in dishes or 6-well plate were harvested. The 
cells were firstly washed with ice-cold PBS and collected by scraping. Cell pellets 
were collected by centrifuging at 6000 rpm for 1 min at 4 °C. For longer term storage, 
cell pellets were kept at -80 oC or otherwise subjected to cell lysis immediately. 
 
3.4 Total RNA isolation 
Total RNA was extracted using RNeasy kit from Qiagen (Singapore) 
with modified protocols as described below. For every 10 million cells, 1 ml of TriZol 
reagent (Invitrogen, Life Technologies, Grand Island, NY) was added into the tube 
which contained cell pellet. Cell pellet was homogenized by pipetting. 200 µl 
Chloroform (Sigma Aldrich, Saint Louis, MO, USA) was added and the tube was 
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vortexed for 15 sec. The tube was incubated on ice for 2-3 min and then spun at 
10,000 rpm for 15 min at 4 °C. The clear aqueous phase was transferred into a new 
tube, and an equivolume of 70% ethanol (around 0.5 ml) was added into the new tube. 
700 µl of the sample was transferred into RNeasy Mini column, and subsequent RNA 
isolation procedure was performed according to manufacturer’s instruction. The 
concentration of total RNA was determined by NanoDrop (Thermo Scientific, 
Wilmington, DE, USA). The 260/280 nm absorbance ratio of the total RNA was 
maintained between 1.9 and 2.1.  
 
3.5 cDNA synthesis 
 
A system of 10 µl containing specific amount of total RNA, primer, 
dNTP mix (10mM), diethylpyrocarbonate (DEPC)-treated water was prepared. The 
reaction mix was incubated at 65 °C for 5 min, and at least at 4 °C for 5 min for the 
annealing of the Oligo-dT primers to the mRNAs. After that, the tubes were taken out 
and put on ice, and 10 µl of synthesis mix was added in the system. The synthesis mix 
contained 2.0 µl of 10×buffer, 4 µl of MgCl2 (25mM), 2µl Dithiothreitol (DTT) 
(0.1M), 1µl RNase OUT (40U/µl), 1µl SuperScript III RT (200 U/µl). Then 10 µl of 
synthesis mix was added into the previous reaction mix, which was then incubated for 
50 min at 50 ºC and cooled to 4 oC. After that, 1 µl of RNase H was added and 
incubated at 37 °C for 20 min.  The tubes were stored at -20 °C until further usage.   
 
3.6 Primer design and gel electrophoresis 
 
Primers were purchased from 1st BASE (Singapore). Two primers have 
been optimized for further experiments. The primers were designed using Primer 3 
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software (version 4.0, http://frodo.wi.mit.edu/primer3/). Forward primer for Tyro3 
was 5’-CGGTAGAAGGTGTGCCATTT-3’, reverse primer 5’-
TGGGTCACCCCTGTTACATT-3’. GAPDH was used as reference gene. The 
sequence of forward primer for GAPDH was 5’-ATGTTCGTCATGGGTGTGAA-3’, 
the sequence of reverse primer for GAPDH was 5’-TGTGGTCATGAGTCCTTCCA-
3’. To test the suitability of primers for real-time polymerase chain reaction (PCR), 
PCR amplifications were performed with KOD hot start polymerase (Novagen, 
Madison, WI). PCR was carried out in 50 µl reaction volumes containing 2 µg cDNA 
templates, 2 mM dNTPS,  25 mM MgSO4, 10×Hot start buffer and 10 µM forward 
and reverse primers. SYBR®-safe (Invitrogen, Singapore) was used to stain DNA 
bands. 50× Tris- acetate- EDTA (TAE) buffer was prepared with 2.42 g/ml Tris, 
57.1% (v/v) acetate and 0.05 mol/L ethylenediaminetetraacetic acid (EDTA). Hot 
start polymerase from MERCK (Darmstadt, Germany) was used to amplify DNA. 
The PCR thermal cycling condition was: hold in 50 ºC for 10 min; for each cycle, 
denature in 85 ºC for 15 sec; anneal in 60º for 1 min and cycled 38 times. Next 
amplified DNA was examined by gel-electrophoresis using 1.5% agarose gel. The 
voltage for electrophoresis was set at 60-100V and left to run for 30 min. After gel 
electrophoresis, the gel was stained in Sybr-safe (Invitrogen) reagent for around 30 
min and was visualized under UV illumination. Single band at the expected size 
indicates the specificity for the targeted amplicon.  
 
3.7 RT-PCR to detect Tyro3 expression on transcriptional level 
 
Quantitative real-time PCR (qRT-PCR) was performed in triplicates on 
the ABI7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA). 
Each reaction contained 4µl synthesized cDNA, 2 µl each of 10 µM forward and 
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reverse primers, 2 µl nuclease-free water and 10 µl Power SYBR Green PCR Master 
Mix (Applied Biosystems). The cycle program for quantitative real-time was hold in 
50 ºC for 10 min; for each cycle, denature in 85 ºC for 15 sec; anneal in 60 ºC for 1 
min for a total of 40 cycles. Gene expression was analyzed with the 2-∆∆Ct formula 
after normalizing to GAPDH. ∆Ct=Ct(Tyro3)-Ct (GAPDH), ∆∆Ct=∆Ct(tumor)-
∆Ct(normal). 
 
3.8 Harvesting cells for western blot   
 
To harvest cells for western blotting, they were first washed with ice 
cold PBS. Cell scraper was used to dislodge cells from its monolayer in culture. Cells 
were transferred into microcentrifuge tubes. Tubes were spun at 5000 rpm for 2 min 
and supernatant was removed. The cell pellet was subsequently lysed with a buffer 
(containing 50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Triton-
X-100, 10 mM sodium pyrophosphate) containing protease and phosphatase inhibitors 
(10 mM sodium fluoride, 2 mM sodium orthovanadate, 1 mM 
phenylmethylsulfonylfluoride, 0.1 µg/ml aprotinin) by gentle mixing in a rotating 
platform for 30 min at 4ºC. To enhance the detection of Tyro3, a membrane bound 
protein, a separate lysis buffer consisting of 20 mM Tris HCl (pH 8.0), 137 mM NaCl, 
10% glycerol, 1% Nonidet P-40 and 2 mM EDTA was also used. Unless stated 
otherwise, chemicals were obtained from Sigma. After lysing cells, the tubes were 
centrifuged at 13,000 rpm for 10 min.   
After mixing for 30 min, cells were centrifuged at 13,000 rpm for 15 min. The 
supernatant was transferred into a new tube, and the supernatant was used to test the 
protein concentration. Protein concentrations were determined by bicinchoninic acid 
(BCA) method (Pierce, Rockford, IL). Standard curve was derived from varying 
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concentrations of albumin solution (2 mg/ml stock), which include 100, 200, 400, 600, 
800, 1000, 1200 µg/ml. Water blank was determined as negative control. Quality of 
protein concentration determination is based on R value of standard curve close to 1.0. 
Then the concentration of unknown protein could be determined by standard curve.  
 
3.9 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 
For Western blotting, equal amounts of proteins prepared and quantified 
as described earlier were resolved with 7.5% SDS-PAGE. The gels generally consist 
of acrylamide, bisacrylamide, SDS and a Tris-Cl buffer with adjusted pH. 7.5% 
separating gel (20 ml) contains 9.8 ml H2O, 5 ml 30% Bisacrylamide, 5 ml 4×Tris 
buffer with SDS, 80 µl 10% ammonium persulfate (APS), 32 µl N,N,N',N'-tetra 
methylene diamine (TEMED). The pH for stacking gel is 8.0. The pH for separating 
gel is 6.8. 10% APS (Sigma-Aldrich) and TEMED (Merck Pte. Ltd., Singapore) are 
added when the gel is to be polymerized. 30-50 µg protein samples were added into 
each well. Protein ladder was also loaded as reference. The voltage for SDS-PAGE 
was firstly set as 60 V; upon loading dye crossing into the separating gel, the voltage 
for SDS-PAGE was increased to 100 V. 
 
3.10 Western Blot 
 
Semi-dry transfer technique was used to transfer the protein in gel on 
polyvinylidene difluoride (PVDF) membrane. The current for semi-dry transfer was 
around 45 mA per membrane.  Then the protein in gel was transferred onto membrane 
by semi-dry transfer. The time for semi-dry transfer is around 2 hours and 20 minutes. 
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After transfer, membranes were blocked with milk using PBS with 0.05% (v/v) 
Tween 20 and 5% (w/v) non-fat milk for about 2 hours at room temperature. After 
blocking, blots were incubated in respective antibodies diluted in PBS with 0.05% 
(v/v) Tween 20 and 5% (w/v) non-fat milk. Primary antibody for Tyro3 was from 
Santa Cruz Biotechnology (Santa Cruz, CA), beta-actin from Abcam (Cambridge, 
MA). Secondary antibodies were anti-mouse and anti-rabbit Horseradish Peroxidase 
(HRP)-conjugated antibodies (Pierce). Incubations were performed overnight on a 
shaker which was placed in refrigerator (around 4 °C). β-tubulin antibody was diluted 
for 1,000 times in 5% milk/phosphate-buffered saline with Tween 20 (PBST) and 
incubated for overnight. Secondary antibody was anti-rabbit secondary antibody 
(which was diluted for 10,000 times in 5% milk/PBST) for around 2 hours. 
Chemiluminescence substrate used was West Dura Extended (Pierce).  
For some western blots, an alternative condition was applied to improve 
on the detection signals: the membranes were blocked in PBS with 0.05% (v/v) 
Tween 20 and 5% (w/v) for overnight at 4˚C. The blot containing Tyro3/β-actin was 
incubated in a tube containing anti-rabbit Tyro3 antibody (1000× in PBS with 0.05% 
(v/v) Tween 20 and 5% (w/v) non-fat milk) at room temperature for 4 hours. After 
washing, the membranes were probed with secondary antibody for 2 hours at room 
temperature and the detection method was described as shown above.   
 
3.11 Knockdown of Tyro3 by siRNA 
 
Tyro3 is silenced in cell culture models, which was performed using 
siRNA.  siRNA which can target Tyro3 and scrambled siRNA were purchased from 
Dharmacon (Chicago, IL).  The transfection reagent Oligofectamine was from 
Invitrogen. The sequence of siRNA targeting Tyro3 were shown as below. Tyro3 
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siRNA10: ACGCUGAGAUUUACAACUA. Tyro3 siRNA 11: 
GCGAUGAACUAAAGGAAAA. To perform Tyro3 silencing, cells were plated into 
6-well plate one day before transfection. Approximately 100,000 cells were seeded 
per well. Transfection was performed when the cell reaches 60% confluent. 24 h after 
seeding, cells were transfected with 100 nM non-targeting control siRNA and tyro3 
siRNA using Oligofectamine reagent (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. Briefly, siRNA: Oligofectamine complexes were added 
to the serum-free medium and incubated for 5 hours. Tube A was consisted of 4 µl 
Oligofectamine and 30µl serum free medium, tube B was consisted of 5.2 µl siRNA 
and 160.8 µl medium. After incubation for 5 min, tube A was added into tube B to 
make the siRNA: Oligofectamine complexes. After incubation for 30 min, the 
complexes were added to the cells. Cells were then replenished with medium with 
10% fetal calf serum (FCS) and incubated for another 72 hrs. The efficiency of 
siRNA knockdown was tested by RT-PCR and Western Blot. Any cell morphological 
changes were also monitored be observing for visual changes using light microscope.  
  
3.12 Cell Titer-Glo 
48h post-transfection with tyro3 targeting siRNA, eight replicates 
(10,000 cells per/well) were seeded in 96-well plate. After incubating for 48 h, 
CellTiter-Glo luminescent assay (Promega, Madison, WI) was performed to measure 
Adenosine Triphosphate (ATP) content as a gauge of the viable cell count. Assay was 
performed according to manufacturer’s instruction. Luminescence was detected with 
SpectraMax M5 (Molecular Devices) and results were expressed in relative 




3.13 Statistical analysis 
 
Statistical analysis was performed for the analysis of RT-PCR results 
and to establish correlations between the expression of Tyro3 and clinico-pathological 
data. SPSS software was employed for most of such analysis. Results were considered 
significant when p value was below 0.05. T test, One-Way ANOVA and Chi-square 
were used to analyze the results. T-test and One-Way ANOVA were used to analyze 





4.1 Overexpression of Tyro3 in HCC patients 
 
57 pairs of HCC patient samples were obtained from our clinical 
collaborator at the National University Hospital (NUH). These samples were supplied 
in the form of total RNA extracted from both HCC tissue and the adjacent normal 
liver tissue from the patients [38]. A former research student in the group has 
previously synthesized cDNA from the total RNA samples (manuscript under review). 
Here, we quantified the expression of Tyro3 in the tumors by RT-PCR and 
normalizing the levels against the respective paired normal tissues. In our study, 
overexpression is defined as fold change between tumor and normal tissue of greater 
than 2-fold, whereas low expression is defined as the fold change between tumor and 
normal tissue of less than 0.5. Two-fold threshold provides a reasonably significant 
cut-off for transcript level changes which is commonly used as a benchmark for 
overexpression. We noted that about 50% of the patients exhibited over expression of 
Tyro3 in the tumor tissues. This also represents the biggest subgroup of the HCC 
patients in our study (Figure 3). As shown in Figure 4, the highest fold change 
detected was ~20-fold in one specific patient, and 7 out of 57 patients demonstrated 
overexpression of greater than 10-fold. Hence, this overexpression warrants further 


















Figure 3 Overexpression of Tyro3 in patient samples. 
Overexpression is defined as the fold change between tumor tissue and normal tissue 
of more than 2.0; medium expression is defined as fold change between tumor tissue 
and normal tissue in the range of 0.5-2.0. 
 
4.2 Correlation of Tyro3 expression with clinical data 
 
4.2.1 Correlation of Tyro3 expression with etiology 
 
Given the frequent overexpression of Tyro3 mRNA in our patient 
samples, we investigated the correlation between Tyro3 expression profile and the 
clinic-pathological data of the patients. For these analyses, we define statistical 
significance as p value less than 0.05, using either chi-square or t-test analysis. The 
complete set of clinic-pathological data of the 57 patients is shown in Table 3. 
Specifically, it was shown that Tyro3 expression exhibited significant correlation with 
the etiology of the disease. Patients with HBV infection exhibited higher average 
Tyro3 overexpression in the tumors vs. normal tissue. Higher number of HBV 
infected patients were detected with two-fold or greater expression of Tyro3 
compared to HCC patients without HBV infection based on chi square analysis. This 
information enables us to stratify our patients into low, medium and high subgroups. 





















Table 3 Clinico-pathological data (courtesy of Poh Wei Jie) 
                                                                                  Value                   Distributions 
Median age (95% CI)                                                58.07            (51.44, 61.71) 7-84 
Gender                              Female                              11                 19.64%                                 
                                          Male                                 45                  80.36% 
Race                                  Chinese                            39                  69.64% 
                                          Indian                                5                    8.93% 
                                          Malay                                2                    3.57% 
                                          Others (Indonesian,           9                  16.07% 
                                          Pakistani, Myanmar) 
Etiology                            HBV                                 41                73.21%  
                                          HCV                                  3                  5.36% 
                                          Alcohol                              1                  1.79% 
                                          Cryptogenic                      11                19.64%  
Outcome                           Alive                                 18                 32.14%        
                                          Death                                17                 30.36% 
                                          Recurrence                       10                 17.86% 
                                          LOT                                  11                 19.64% 
Mean ALT(U/ml) (95% CI)*                                   58.26       (42.44,74.07) 14-343 
Mean AST(U/ml)  (95%CI)*                                   68.61        (52.06,85.16) 17-313 
Mean AFP(U/ml) (95%CI)^                                   23030(6348,39713)1.1-308590.0 
                                          <400U/ml                        30                 54.55%    
                                          >400U/ml                        25                 45.45% 
Tumor multiplicity       Single tumor                         34                 60.71% 
                                     Multiple tumors                    22                 39.29% 
Tumor histology           Poor                                      15                 26.79% 
(Differentiation)           Moderate                               33                 58.93% 
                                      Well to moderate                   1                    1.79% 
                                      Well                                       6                  10.71% 
                                      Fibrolamellar variant             1                    1.79% 
Tumor diameters                                 8.54                 (7.243, 9.828) 1.1-22.0 
Cirrhosis                         Positive                                37                 66.07% 
                                       Negative                               19                 33.93% 
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Vascular invasion           Yes                                       30                53.57% 
                                        No                                        19                33.93%  
                                        No report                               7                12.50% 
  *n=51 
  ^n=55 
 
Table 4 Correlation between HBV infection and Tyro3 overexpression (ratio) 
          Etiology             Number of patients               Tyro3 expression             p value 
                                                                       > 2 fold        0.5-2        <0.5 
           HBV                         41                20 (48.8%)  18 (43.9%)    3 (7.3%)      0.05 
           Non-HBV                 15                  5 (33.3%)    5 (33.3%)    5 (33.3%)     
High Tyro 3 expression is defined as 2-fold or more changes between tumor and 
normal tissue; medium expression is defined as the fold change in the range of 0.5-2.0; 
low expression is defined as the fold change between tumor tissue and normal tissue 
of less than 0.5 
 
 
Figure 4 Fold change of Tyro3 expression between tumor tissue and normal 
tissue in individual patient.  
Results indicated a total of 55 pairs of patient samples were tested. Overexpression is 
defined when the fold change between tumor tissue and normal tissue is above 2.0. 
 
 
4.2.2 Correlation of Tyro3 expression with AFP level 
 
AFP is an important clinical biomarker for HCC detection [83]. In about 
60-70% of the patients, increased AFP correlates with disease severity [84]. Using the 
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clinical threshold of 500 ng/ml for high AFP expression, we found that patients with 
high AFP exhibited higher expression of Tyro3 with an average fold change of 5.6 
compared to 2.5 in patients with lower AFP group. The results are shown in Table 5. 
   
Table 5 Correlation between Tyro3 expression fold change and AFP level 
     AFP level (ng/ml)       Number of patients           Average fold change       p value 
          ≤ 500                                31                                2.52±3.27                     0.01  
          > 500                                24                                5.60±5.43 
At the clinical threshold of 500 ng/ml, patients with high AFP exhibited higher 
expression of Tyro3. 
 
4.2.3 Correlation of Tyro3 expression with AST level 
 
AST and ALT are clinical biomarkers in serum. The expression of AST 
and ALT correlates with hepatocellular damage and serves as an indirect indicator of 
HCC disease status. AST is an enzyme in the liver, when the liver function is 
damaged, AST will be released into the blood. Here we examine correlation if any 
between Tyro3 expression and AST in HCC patients. For the patient cohort with 
serum AST higher than clinical level of 40 IU, more than 50% patients demonstrated 
high Tyro3 expression in the tumor. Patients with AST level below 40 U/I have 
relatively lower ratio of Tyro3 overexpression. The results are shown in Table 6. 
 
Table 6 Correlation between AST level and overexpression of Tyro3 
AST level (U/I)       Number of patients             Tyro3 expression                    p value 
                                                                           High           Low 
        >40                            30                        16(53.3%)    14(46.7%)                  0.04 
        ≤40                            21                          5(23.8%)    16(76.2%) 
At the clinical cutoff of 40 U/I, patients whose AST levels were above 40 U/I have 





4.2.4 Correlation of ALT level with overexpression of Tyro3 
 
Similar to AST, ALT is another important marker for liver function and 
elevated levels correlates with liver injury. Our results demonstrated that patients with 
ALT level higher than clinical level of 35 U/I, the ratio of Tyro3 over expression in 
HCC patients were also significantly higher compared to patients whose ALT level is 
below 35 U/I. The results are shown in Table 7. 
 
Table 7 Correlation between Tyro3 over expression and ALT level 
ALT level (U/I)           Number of patients        Tyro3 expression             p value 
                                                                             High             Low 
        >35                                 31                        17(54.8%)   14(45.2%)      0.01 
        ≤35                                 20                          4(20.0%)   16(80.0%) 
At the clinical cutoff of 35U/I, patients whose ALT levels were above 35 U/I have 
higher ratio of Tyro3 overexpression than patients whose ALT levels were below 35 
U/I.  
 
 4.2.5 Correlation between Tyro3 over expression and tumor size 
 
A way to measure tumor aggressiveness is by measuring the tumor 
growth. Here, we found that Tyro3 overexpression in HCC patients significantly 
correlated with tumor size. The tumor size is represented by the tumor diameter at its 
longest dimension. When Tyro3 is overexpressed, the average tumor size is 
significantly bigger than that of patients without Tyro3 overexpression. 51% of 
patients’ tumors with tumor diameter of more than 3 cm showed overexpression of 
Tyro3 with p value less than 0.05. Whereas, none of the patients with tumor diameter 





Table 8 Correlation between tumor size and overexpression of Tyro3 
Tumor size (cm)        Number of patients                   Tyro3 expression            p value 
                                                                                    High              Low 
         >3                                49                             25 (51.0%)     24 (49.0%)        0.02                           
         ≤3                                 7                                0 (0%)            7 (100%)                                  
At the cutoff of 3cm, patients with tumors more than 3 cm have higher ratio of Tyro3 
overexpression than patients whose tumors were smaller than 3 cm. 
 
4.3 Tyro3 expression in different liver cancer cell lines 
 
Based on the strong correlation between Tyro3 expression and various 
clinic-pathological characteristics in HCC, we embarked on subsequent in vitro 
investigation to validate the in vivo observation as well as to gain mechanistic insight 
on the role of Tyro3 in this disease. Our first step was to select suitable HCC cell lines 
as our experimental models. Hence, we surveyed the expression of Tyro3 expression 
across different HCC cell lines, which include HepG2, Hep3B, Primary Liver Cancer 
(PLC)/PRF/5, Sk-Hep1, Huh7, as well as non-cancerous liver cell lines THLE2 and 
Hs1.Li. We tested the Tyro3 expression by RT-PCR and immunoblotting.  Our results 
demonstrated that most liver cancer cell lines overexpressed Tyro3 when comparing 
with THLE2 and Hs1.Li cell lines. The highest expression of Tyro3 was found in 
Hep3B, which is a cell line carrying HBV infection (Table 9). The second highest 
expression of Tyro3 was found in HepG2 and the third highest was found in Huh7. 
Subsequently, western blotting confirmed the transcriptional expression results where 
Hep3B was also found to be the highest Tyro3 protein expressing cells (Figure 6). 
Huh7 has the next highest protein expression besides Hep3B. As Tyro3 is expressed 
highly in Hep3B cell line, it is meaningful to study the role of Tyro3 in HCC 
















Figure 5 Comparison of Tyro3 expression in different liver cancer cell lines on 
transcriptional level. 
RT-PCR was performed to test the expression of Tyro3 in different cell lines. The 
expression of Tyro3 was normalized against respective GAPDH as housekeeping 
control and fold-change normalized against Hs1.Li as normal hepatocyte cell line. 
Each fold change is expressed as the mean of duplicate runs. 
 
Table 9 Hepatitis B status of HCC cell lines used 








           Ratio (Tyro3/β-tubulin):   1.38            0.24         3.46 
 
Figure 6 Tyro3 expressions in Huh7, HepG2 and Hep3B liver cancer cell lines. 
Whole cell lysate were harvested from Hep3B, Huh7 and HepG2 cells. 50 µg protein 
lysate was loaded and resolved with 7.5% SDS-PAGE gel. Western blot was 









































expression was quantified densitometrically (Image J) and presented as a ratio of 
Tyro3:β-tubulin. 
 
4.4 Knockdown of Tyro3 in Hep3B cell line 
 
To study the effect of Tyro3 on cell growth properties of HCC cells, 
knockdown of Tyro3 was performed to silence Tyro3 expression. Tyro3 is knocked 
down in high-expression cell line, Hep3B cell line using siRNA either si10 or si11. 
Here, we found 80-90% of Tyro3 was silenced using RT-PCR as shown in Figure 7. 
Hence, the protocol was adopted for subsequent phenotype-based assay to validate the 
effect of Tyro3.  






















Figure 7 Tyro3 is silenced in Hep3B cell line. 
Hep3B cells were transfected with either scrambled siRNA, si10 or si11, using 
oligofectamine according to manufacturer’s instruction. cDNAs we 
re prepared from transfected cells after 48hrs, Tyro3 transcript was assessed via RT-
PCR. 
 
4.5 Effect of Tyro3 silencing on Hep3B cell viability 
 
Cell Titer Glo was used to determine the impact of Tyro3 silencing on 
cancer phenotype. As a specific indicator of intracellular ATP levels, the assay 
provides an early indication if Tyro3 signaling may alter important regulators of cell 
proliferation and cell viability machineries after Tyro3 knockdown. After 72 h of 
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silencing, we found both siRNA constructs effectively reduced cellular ATP levels to 
about 60% of control as shown in Figure 8. Our data indicates that Tyro3 plays an 












































Figure 8 Silencing of Tyro3 reduces cell viability. 
Hep3B cells were treated with scrambled siRNA, si10 or si11 for 48 hours later. Cell 
viability was tested using Cell Titer-Glo. Results are shown as percentage of cell 















5.0 DISCUSSION  
The value of molecular targeted therapy to cancer treatment is about 
finding a unique signaling mechanism specific to the cancer that may be accountable 
for the manifestation of the disease. The pivotal role of Bcr-Ab1 translocation in 
chronic myelogenic leukemia, activating mutation of EGFR in non-small cell lung 
cancer, as well as the amplification of HER2 in breast carcinoma are some of the 
notable examples that energized widespread efforts to consider this relationship in 
other cancer types [85]. Among the molecular targets identified to date, tyrosine 
kinase family has found greatest success with 9 agents that have obtained FDA 
approval as of 2010 (http://www.fda.gov). However, a reciprocal challenge to the 
specificity of tyrosine kinase mediated cell signaling is that every cancer tissue type 
may also utilize a different subset of kinases for its growth and maintenance. Hence, 
an effective application of tyrosine kinase inhibitors must involve an in-depth 
understanding of a particular tyrosine kinase and its role towards the malignancy of 
interest. In the case of HCC, a specific target remains elusive. Associations have been 
made between the disease and various tyrosine kinases but none appear to be single-
handedly accountable for most of the observations. In this study, we have focused on 
a relatively uncharacterized tyrosine kinase, Tyro3, in the context of liver cancer, 
based on promising preliminary study suggesting its effect on HCC cell line. 
Accordingly, we have chosen to embark on a search for correlations 
between Tyro3 expression and clinical data, as an entry point to this study. We 
envisioned that any link between increased Tyro3 expression and disease 
manifestation will provide important basis and direction for subsequent elucidation of 
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mechanism as well as further characterization of Tyro3 as a drug target. Firstly, the 
survey of 57 HCC patients revealed that almost half of them exhibit a significant 
elevation of Tyro3 transcript expression in tumor as compared to the adjacent normal 
tissue. This finding suggests the possibility that increased Tyro3 may be implicated in 
the transition of HCC from the normal to the tumor state. This is an important 
discovery that provides the early basis to support a further investigation into this area. 
The elevation observed in our study parallels the upregulation of AXL in HCC, 
another member of the TAM receptor family, which was also reported previously [39]. 
Furthermore, it mirrors the upregulation of Tyro3 seen in other malignancies such as 
melanoma and lung carcinoma [74, 75]. 
In order to associate the upregulation of Tyro3 in HCC to disease 
outcome, we performed a series of statistical analyses to detect correlation between 
expression and clinic-pathological states. We found that increased Tyro3 expression 
correlated well with higher levels of liver injury markers such as ALT and AST. 
These markers are common indicators of hepatocellular damage, which are also 
important sequelae of HCC. Therefore, the association with high Tyro3 may indicate 
a possible role to the progression of the disease. This link warrants further 
investigation using in vitro model system, which will be discussed subsequently. 
Besides hepatocellular dysfunction, Tyro3 exhibited strong correlation 
with a number of direct markers of HCC. Higher AFP levels were shown to be linked 
to higher levels of Tyro3. This was also accompanied by diagnoses of larger tumor 
size at the point of surgical resection. The exact role of AFP in HCC is not known. 
However, this is a serum protein secreted in about 60-70% of all HCC patients [84]. 
In these patients, the level of AFP correlates well with the severity of the disease. In 
another words, a patient with a high AFP level may suffer a worse prognosis than 
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another with lower AFP. On the other hand, a larger tumor underpins the immense 
growth potential of the cancerous cells contributing to the tumor mass. Therefore, the 
combination of both increased tumor size and higher Tyro3 levels suggest that Tyro3 
may have a significant role in the disease. 
An interesting observation we made was the connection between 
elevated Tyro3 and the HBV-carrier status of the patient. We found that a much larger 
percentage of HBV carriers demonstrated higher expression of Tyro3 in their tumors 
versus the adjacent normal liver tissue. This raises a specific question with regards to 
the role of Tyro3 signaling on the etiology of the disease. Since the late 1990s, it was 
reported that HBV DNA could integrate into host DNA near the domains of tyrosine 
kinases such as EGFR. HBV gene product, HBx, was also shown to affect the 
transactivation of EGFR [86]. This mechanism is believed to transmit 
hyperproliferative signals for cells via downstream ERK phosphorylation and increase 
cell cycling. Similar studies in HCV have also demonstrated the activation of ERK 
phosphorylation and an increase in the aggressiveness of the consequent HCC [87]. 
Since these founding works, other investigators have also reported the possible 
involvement of other tyrosine kinases whereby SRC kinase family and FAK were 
shown to be activated through a direct association with HBx protein [37, 88]. More 
recently, other studies have also alluded to an increase in the expression of proto-
oncogenes such as c-KIT (a key receptor tyrosine kinase found to be linked to the 
pathogenesis of gastrointestinal stromal tumors (GIST) particularly among HBV 
carriers who progressed into chronic hepatitis, cirrhosis or HCC [52]. The major 
implication for these findings is that aberrant expression and activation of tyrosine 
kinase can play important role on the hepatocarcinogenesis, thereby making them 
potential drug targets for both therapeutic and prophylactic purposes. Our observation 
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of a positive correlation between increased Tyro3 expression and HBV-carrier status 
therefore deserves further characterization. 
Clinical correlation studies provide the relevance and rationale that 
Tyro3 may have a role to play HCC. Yet, it is not clear whether the upregulation of 
Tyro3 is a cause or an effect of disease progression. For this reason, our principal 
approach to establish the relationship is to perform in vitro studies to investigate 
consequence of activating or silencing Tyro3 function. This will enable us to 
determine the functional role of Tyro3 in HCC as well as to gain mechanistic insights 
for the phenotype it may generate. To support this effort, we selected suitable HCC 
cell lines that express inherently high levels of Tyro3 as in vitro models. From our 
available HCC cell lines, we found Hep3B, a HBV-infected HCC cell line, to exhibit 
the highest level of Tyro3 expression. It is interesting to note that even from our 
limited pool of cell lines, we already observed stronger expression among the HBV-
infected ones, similar to the trend observed from our clinical data. Hence, our data 
substantiates the growing evidence of high Tyro3 expression in cancer tissues as 
documented by Human Protein Atlas (http://www.proteinatlas.org) for protein 
expression, and the GNF SymAtlas (http://www.biogps.gnf.org) for mRNA 
expression.   
To establish the functional consequence of Tyro3 in HCC cell line 
model, we performed gene silencing of Tyro3 using chemically synthesized siRNA. 
This approach allowed us to investigate the direct effect of Tyro3 silencing on cancer 
phenotype, of which we have chosen cell proliferation as a proof of concept. Very 
clearly, we  observed a significant suppression of cell viability in response to Tyro3 
knock-down, using intracellular ATP production as a surrogate marker for viability.  
Therefore, not only is Tyro3 contributing to cell survival in HCC cell line, this result 
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also suggests that Tyro3 may play a pivotal role among other tyrosine kinases that 
may also be concurrently active in this cell line. This outcome is a key consideration 
of suitability in molecular-targeted therapy. The protagonist should play a dominant 
role in maintaining the cancer phenotype so that its inhibition can be effective as 
therapy. 
That said, our finding is at best, preliminary, in its current state. Further 
characterization is needed in a few directions. Firstly, we need to ensure that the effect 
seen in Hep3B is not peculiar in this cell line. The same study should be replicated in 
other HCC cell lines. Secondly, the effect of Tyro3 silencing on other cancer 
phenotypes should also be monitored. AFP secretion is a specific marker for HCC 
progression and the outcome of Tyro3 inhibition/silencing on its levels would suggest 
whether such therapy could alter the prognosis of the disease. Intra-hepatic and extra-
hepatic metastases are common causes of death for HCC [89]. Recent breakthroughs 
in pharmacotherapy of HCC using tyrosine kinase inhibitors such as sorafenib are 
thought to involve anti-metastatic activities through blocking angiogenesis [90]. 
Therefore, examining the effect of Tyro3 on different aspects of metastasis (e.g. 
cellular invasion, epithelial-mesenchymal-transition, angiogenesis) should also be 
included as part of the repertoire of cancer phenotypes. Finally, biochemical 
investigation should be included to understand the cellular signaling perturbation as a 
result of Tyro3 silencing. The signaling cascade that propagates Tyro3 
phosphorylation and activation has not been fully understood. The target genes of 
such pathways that may be specific to liver physiology should also be identified in 
order to pinpoint other sites of intervention to support pharmacotherapy. Some 
specific pathways to consider include examining PI3K/AKT and ERK/MAPK 
phosphorylation as principal downstream regulators of cancer phenotypes. The 
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potential interaction of between Tyro3 kinase signaling and the viral protein, HBx 
should also be studied to establish any mechanistic link that may account for the 
clinical correlation between Tyro3 expression and HBV infection in patients. Also, 
cross-talks in cell signaling between tyrosine kinases contribute to treatment 
resistance. Therefore, such biochemical understanding will help us to recognize other 
targets that should be inhibited concurrently to enhance treatment response.  
In our subsequent investigations, we also believe that we can draw 
reference from the findings of Tyro3 in other cancer types. In melanoma, it has been 
reported that Tyro3 could induce Melanocyte-specific MITF (MITF-M) expression 
[75]. It was shown that silencing of Tyro3 by shRNA in vitro resulted in a decrease in 
cell number with a corresponding decrease in cells undergoing apoptosis. When 
Tyro3 is knocked down in vivo, tumor shrinkage was observed in a time-dependent 
manner. It is suggested that Tyro3 may play its role in melanoma development 
through signaling pathway that involves microphthalmia-associated transcription 
factor (MITF) and implicate this as a possible drug target for development. 
On a separate note, Tyro3 perturbation may lead to a change in 
expression levels of Axl and Mer. It is possible that the change in expression of one 
member of the TAM family may result in expression changes of the other two 
members due to the redundancy of signaling. By knowing more about the 
mechanisms and their involvement in HCC progression of these tyrosine kinases, as 
well as exploring more tyrosine kinases that are related to HCC development, we can 
have a better understanding of HCC development. This will lead us to find more 




The knowledge gap of Tyro3 signaling in cancer and liver physiology in general is 
immense. This project provides a timely model and an appropriate research question 
to address some of these issues in a more holistic manner. Overall, we hope that these 
endeavors will provide additional tools in the understanding and treatment of an 




6.0 CONCLUSION AND FUTURE 
DIRECTIONS 
Our project set out to investigate the role of tyrosine kinase Tyro3, a 
relatively uncharacterized tyrosine kinase in HCC. Using a representative resource of 
HCC patients’ samples obtained from National University Hospital, we first reported 
a significant overexpression of Tyro3 in about half of the patient samples. Importantly, 
by correlating Tyro3 expression with clinical data, we found elevations in Tyro3 to 
correspond to individuals with concurrent HBV infection, higher levels of tumor 
marker AFP, as well as higher liver disease markers ALT and AST. These outcomes 
provide strong basis to support further in vitro work to elucidate the mechanistic role 
of Tyro3 in HCC disease progression. Accordingly, we surveyed a number of cell 
lines and selected a high Tyro3-expressing HCC line, Hep3B, as an in vitro model for 
investigation. We successfully silenced the expression of Tyro3 and found a 
significant effect of Tyro3 in maintaining the proliferation of Hep3B. 
 Therefore, this work provided critical preliminary data that implicate 
Tyro3 as a new tyrosine kinase target which may play crucial role in the pathogenesis 
and progression of HCC. Through this effort, we have also developed a set of tools 
that enables us to probe further into the specific role of Tyro3 in a relevant cell type.  
Given the huge heterogeneity of the disease, we subscribe to the belief 
that Tyro3 may play a contributory role as part of the complex signaling that 
maintains the phenotype of HCC. However, the relative importance of its contribution 
with respect to other known oncogenic signaling pathways awaits further 
investigation. Therefore, with a better understanding of how Tyro3 participate in this 
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process, possible development of Tyro3 as a potential drug target or as an adjuvant 
therapy can be visited both objectively and systematically (Figure 9). 
 



















There is correlation 
between Tyro3 
overexpression with 
liver injury and HCC 
markers 
Silencing of Tyro3 
expression in Hep3B 
can reduce cell 
viability. 
Signaling pathways 
Tyro3 is involved in are 





[1] El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and 
molecular carcinogenesis. Gastroenterology 2007;132:2557-76. 
[2] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of 
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 
[3] Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma--
epidemiological trends and risk factors. Dig Dis 2009;27:80-92. 
[4] Yeh SH, Chen PJ. Gender disparity of hepatocellular carcinoma: the roles of 
sex hormones. Oncology 78 Suppl 1:172-9. 
[5] McKillop IH, Schrum LW. Role of alcohol in liver carcinogenesis. Semin 
Liver Dis 2009;29:222-32. 
[6] Stickel F, Schuppan D, Hahn EG, Seitz HK. Cocarcinogenic effects of alcohol 
in hepatocarcinogenesis. Gut 2002;51:132-9. 
[7] McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper ML, Zhou T, et al. 
Susceptibility to hepatocellular carcinoma is associated with genetic variation 
in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci U S A 
1995;92:2384-7. 
[8] Hui AY, Friedman SL. Molecular basis of hepatic fibrosis. Expert Rev Mol 
Med 2003;5:1-23. 
[9] Satyanarayana A, Manns MP, Rudolph KL. Telomeres and telomerase: a dual 
role in hepatocarcinogenesis. Hepatology 2004;40:276-83. 
[10] Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18. 
48 
 
[11] Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular 
carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 42:341-7. 
[12] Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current 
treatment with a focus on targeted molecular therapies. Therap Adv 
Gastroenterol 3:55-66. 
[13] Llovet JM. Updated treatment approach to hepatocellular carcinoma. J 
Gastroenterol 2005;40:225-35. 
[14] Barber K, Blackwell J, Collett D, Neuberger J. Life expectancy of adult liver 
allograft recipients in the UK. Gut 2007;56:279-82. 
[15] Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 
52:762-73. 
[16] Kunzli BM, Abitabile P, Maurer CA. Radiofrequency ablation of liver tumors: 
Actual limitations and potential solutions in the future. World J Hepatol 3:8-14. 
[17] Yeo W, Mo FK, Chan SL, Leung NW, Hui P, Lam WY, et al. Hepatitis B 
viral load predicts survival of HCC patients undergoing systemic 
chemotherapy. Hepatology 2007;45:1382-9. 
[18] Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. Expert 
Opin Emerg Drugs 2006;11:469-87. 
[19] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 
144:646-74. 
[20] Van Meter ME, Kim ES. Bevacizumab: current updates in treatment. Curr 
Opin Oncol 22:586-91. 
[21] Campbell L, Blackhall F, Thatcher N. Gefitinib for the treatment of non-small-
cell lung cancer. Expert Opin Pharmacother 11:1343-57. 
49 
 
[22] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. 
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-
90. 
[23] Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and 
safety of sorafenib in patients in the Asia-Pacific region with advanced 
hepatocellular carcinoma: a phase III randomised, double-blind, placebo-
controlled trial. Lancet Oncol 2009;10:25-34. 
[24] Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, et al. 
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of 
combined sorafenib and rapamycin in vivo. J Hepatol 2009;51:725-33. 
[25] Zhu AX. Development of sorafenib and other molecularly targeted agents in 
hepatocellular carcinoma. Cancer 2008;112:250-9. 
[26] Bennasroune A, Gardin A, Aunis D, Cremel G, Hubert P. Tyrosine kinase 
receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol 
2004;50:23-38. 
[27] Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 
141:1117-34. 
[28] Giannelli G, Sgarra C, Porcelli L, Azzariti A, Antonaci S, Paradiso A. EGFR 
and VEGFR as potential target for biological therapies in HCC cells. Cancer 
Lett 2008;262:257-64. 
[29] Kitisin K, Pishvaian MJ, Johnson LB, Mishra L. Liver stem cells and 
molecular signaling pathways in hepatocellular carcinoma. Gastrointest 
Cancer Res 2007;1:S13-21. 
[30] Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, et al. Reduced 
VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the 
50 
 
Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors. Cancer Res 
71:1573-83. 
[31] Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the 
development and treatment of hepatocellular carcinoma. Oncogene 29:4989-
5005. 
[32] Hopfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scherubl H. 
Targeting the epidermal growth factor receptor by gefitinib for treatment of 
hepatocellular carcinoma. J Hepatol 2004;41:1008-16. 
[33] Scharf JG, Dombrowski F, Ramadori G. The IGF axis and 
hepatocarcinogenesis. Mol Pathol 2001;54:138-44. 
[34] Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Sole M, et al. IGF 
activation in a molecular subclass of hepatocellular carcinoma and pre-clinical 
efficacy of IGF-1R blockage. J Hepatol 52:550-9. 
[35] Hopfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherubl H. 
Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in 
hepatocellular carcinoma cells. Biochem Pharmacol 2006;71:1435-48. 
[36] Luedde T. MicroRNA-151 and its hosting gene FAK (focal adhesion kinase) 
regulate tumor cell migration and spreading of hepatocellular carcinoma. 
Hepatology 52:1164-6. 
[37] Bouchard MJ, Wang L, Schneider RJ. Activation of focal adhesion kinase by 
hepatitis B virus HBx protein: multiple functions in viral replication. J Virol 
2006;80:4406-14. 
[38] Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, et al. Fibroblast growth 
factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein 
51 
 
secretion during hepatocellular carcinoma progression and represents a 
potential target for therapeutic intervention. J Hepatol 2009;50:118-27. 
[39] Tsou AP, Wu KM, Tsen TY, Chi CW, Chiu JH, Lui WY, et al. Parallel 
hybridization analysis of multiple protein kinase genes: identification of gene 
expression patterns characteristic of human hepatocellular carcinoma. 
Genomics 1998;50:331-40. 
[40] Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, et al. AXL receptor 
kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular 
carcinoma. Oncogene 30:1229-40. 
[41] Chen G, Wang Y, Zhou M, Shi H, Yu Z, Zhu Y, et al. EphA1 receptor 
silencing by small interfering RNA has antiangiogenic and antitumor efficacy 
in hepatocellular carcinoma. Oncol Rep 23:563-70. 
[42] Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, et al. 
Differential gene expression of Eph receptors and ephrins in benign human 
tissues and cancers. Clin Chem 2004;50:490-9. 
[43] Itoh S, Maeda T, Shimada M, Aishima S, Shirabe K, Tanaka S, et al. Role of 
expression of focal adhesion kinase in progression of hepatocellular carcinoma. 
Clin Cancer Res 2004;10:2812-7. 
[44] Qiu WH, Zhou BS, Chu PG, Chen WG, Chung C, Shih J, et al. Over-
expression of fibroblast growth factor receptor 3 in human hepatocellular 
carcinoma. World J Gastroenterol 2005;11:5266-72. 
[45] Liu J, Ahiekpor A, Li L, Li X, Arbuthnot P, Kew M, et al. Increased 
expression of ErbB-2 in liver is associated with hepatitis B x antigen and 
shorter survival in patients with liver cancer. Int J Cancer 2009;125:1894-901. 
52 
 
[46] Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, et al. 
Expression and clinical significance of erb-B receptor family in hepatocellular 
carcinoma. Br J Cancer 2001;84:1377-83. 
[47] Neo SY, Leow CK, Vega VB, Long PM, Islam AF, Lai PB, et al. 
Identification of discriminators of hepatoma by gene expression profiling 
using a minimal dataset approach. Hepatology 2004;39:944-53. 
[48] Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm 
Metab Res 2003;35:685-93. 
[49] Lee YH, Yun Y. HBx protein of hepatitis B virus activates Jak1-STAT 
signaling. J Biol Chem 1998;273:25510-5. 
[50] Verbsky JW, Bach EA, Fang YF, Yang L, Randolph DA, Fields LE. 
Expression of Janus kinase 3 in human endothelial and other non-lymphoid 
and non-myeloid cells. J Biol Chem 1996;271:13976-80. 
[51] Chung CY, Yeh KT, Hsu NC, Chang JH, Lin JT, Horng HC, et al. Expression 
of c-kit protooncogene in human hepatocellular carcinoma. Cancer Lett 
2005;217:231-6. 
[52] Kara B, Doran F, Kara IO, Akkiz H, Sandikci M. Expression of c-kit 
protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and 
hepatocellular carcinoma: has it a diagnostic role? Int J Clin Pract 
2008;62:1206-11. 
[53] Mansuroglu T, Baumhoer D, Dudas J, Haller F, Cameron S, Lorf T, et al. 
Expression of stem cell factor receptor c-kit in human nontumoral and tumoral 
hepatic cells. Eur J Gastroenterol Hepatol 2009;21:1206-11. 
53 
 
[54] Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, et al. Somatic 
mutations in the kinase domain of the Met/hepatocyte growth factor receptor 
gene in childhood hepatocellular carcinomas. Cancer Res 1999;59:307-10. 
[55] Xie B, Xing R, Chen P, Gou Y, Li S, Xiao J, et al. Down-regulation of c-Met 
expression inhibits human HCC cells growth and invasion by RNA 
interference. J Surg Res 162:231-8. 
[56] Stock P, Monga D, Tan X, Micsenyi A, Loizos N, Monga SP. Platelet-derived 
growth factor receptor-alpha: a novel therapeutic target in human 
hepatocellular cancer. Mol Cancer Ther 2007;6:1932-41. 
[57] Sun CK, Man K, Ng KT, Ho JW, Lim ZX, Cheng Q, et al. Proline-rich 
tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of 
hepatocellular carcinoma cells through c-Src/ERK activation. Carcinogenesis 
2008;29:2096-105. 
[58] Sun CK, Ng KT, Sun BS, Ho JW, Lee TK, Ng I, et al. The significance of 
proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression 
and recurrence. Br J Cancer 2007;97:50-7. 
[59] Chen Q, Seol DW, Carr B, Zarnegar R. Co-expression and regulation of Met 
and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell 
lines. Hepatology 1997;26:59-66. 
[60] Ito Y, Kawakatsu H, Takeda T, Sakon M, Nagano H, Sakai T, et al. Activation 
of c-Src gene product in hepatocellular carcinoma is highly correlated with the 
indices of early stage phenotype. J Hepatol 2001;35:68-73. 
[61] Tanaka S, Sugimachi K, Yamashita Yi Y, Ohga T, Shirabe K, Shimada M, et 
al. Tie2 vascular endothelial receptor expression and function in hepatocellular 
carcinoma. Hepatology 2002;35:861-7. 
54 
 
[62] Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, et al. 
Involvement of the vascular endothelial growth factor receptor-1 in murine 
hepatocellular carcinoma development. J Hepatol 2004;41:97-103. 
[63] Lian Z, Liu J, Wu M, Wang HY, Arbuthnot P, Kew M, et al. Hepatitis B x 
antigen up-regulates vascular endothelial growth factor receptor 3 in 
hepatocarcinogenesis. Hepatology 2007;45:1390-9. 
[64] Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, et al. Safety 
and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: 
an open-label, multicentre, phase II study. Lancet Oncol 2009;10:794-800. 
[65] Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, et al. Phase II, Open-
Label Study of Brivanib as First-Line Therapy in Patients with Advanced 
Hepatocellular Carcinoma. Clin Cancer Res. 
[66] Lin AY, Fisher GA, So S, Tang C, Levitt L. Phase II study of imatinib in 
unresectable hepatocellular carcinoma. Am J Clin Oncol 2008;31:84-8. 
[67] Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase 
II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. 
J Clin Oncol 2005;23:6657-63. 
[68] Huynh H. Tyrosine kinase inhibitors to treat liver cancer. Expert Opin Emerg 
Drugs 15:13-26. 
[69] Gustafsson A, Bostrom AK, Ljungberg B, Axelson H, Dahlback B. Gas6 and 
the receptor tyrosine kinase Axl in clear cell renal cell carcinoma. PLoS One 
2009;4:e7575. 
[70] Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine 
kinases: biologic functions, signaling, and potential therapeutic targeting in 
human cancer. Adv Cancer Res 2008;100:35-83. 
55 
 
[71] Polvi A, Armstrong E, Lai C, Lemke G, Huebner K, Spritz RA, et al. The 
human TYRO3 gene and pseudogene are located in chromosome 15q14-q25. 
Gene 1993;134:289-93. 
[72] Taylor IC, Roy S, Varmus HE. Overexpression of the Sky receptor tyrosine 
kinase at the cell surface or in the cytoplasm results in ligand-independent 
activation. Oncogene 1995;11:2619-26. 
[73] Taylor IC, Roy S, Yaswen P, Stampfer MR, Varmus HE. Mouse mammary 
tumors express elevated levels of RNA encoding the murine homology of 
SKY, a putative receptor tyrosine kinase. J Biol Chem 1995;270:6872-80. 
[74] Wimmel A, Rohner I, Ramaswamy A, Heidtmann HH, Seitz R, Kraus M, et al. 
Synthesis and secretion of the anticoagulant protein S and coexpression of the 
Tyro3 receptor in human lung carcinoma cells. Cancer 1999;86:43-9. 
[75] Zhu S, Wurdak H, Wang Y, Galkin A, Tao H, Li J, et al. A genomic screen 
identifies TYRO3 as a MITF regulator in melanoma. Proc Natl Acad Sci U S 
A 2009;106:17025-30. 
[76] Hafizi S, Gustafsson A, Stenhoff J, Dahlback B. The Ran binding protein 
RanBPM interacts with Axl and Sky receptor tyrosine kinases. Int J Biochem 
Cell Biol 2005;37:2344-56. 
[77] Lan Z, Wu H, Li W, Wu S, Lu L, Xu M, et al. Transforming activity of 
receptor tyrosine kinase tyro3 is mediated, at least in part, by the PI3 kinase-
signaling pathway. Blood 2000;95:633-8. 
[78] Chen J, Carey K, Godowski PJ. Identification of Gas6 as a ligand for Mer, a 
neural cell adhesion molecule related receptor tyrosine kinase implicated in 
cellular transformation. Oncogene 1997;14:2033-9. 
56 
 
[79] Katagiri M, Hakeda Y, Chikazu D, Ogasawara T, Takato T, Kumegawa M, et 
al. Mechanism of stimulation of osteoclastic bone resorption through 
Gas6/Tyro 3, a receptor tyrosine kinase signaling, in mouse osteoclasts. J Biol 
Chem 2001;276:7376-82. 
[80] Toshima J, Ohashi K, Iwashita S, Mizuno K. Autophosphorylation activity 
and association with Src family kinase of Sky receptor tyrosine kinase. 
Biochem Biophys Res Commun 1995;209:656-63. 
[81] Villanueva A, Llovet JM. Targeted Therapies for Hepatocellular Carcinoma. 
Gastroenterology. 
[82] De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC, et al. 
Identifying intercellular signaling genes expressed in malignant plasma cells 
by using complementary DNA arrays. Blood 2001;98:771-80. 
[83] Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular 
carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim 
Acta 2008;395:19-26. 
[84] Abelev GI, Eraiser TL. Cellular aspects of alpha-fetoprotein reexpression in 
tumors. Semin Cancer Biol 1999;9:95-107. 
[85] Alaoui-Jamali MA. Protein tyrosine kinase signaling diversity and 
susceptibility to targeted kinase inhibitors. Biomed Pharmacother 
2006;60:629-32. 
[86] Miyaki M, Sato C, Sakai K, Konishi M, Tanaka K, Muraoka M, et al. 
Malignant transformation and EGFR activation of immortalized mouse liver 
epithelial cells caused by HBV enhancer-X from a human hepatocellular 
carcinoma. Int J Cancer 2000;85:518-22. 
57 
 
[87] Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling 
K, et al. Activation of the ERK and AKT signalling pathway predicts poor 
prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is 
associated with hepatitis C virus infection. J Hepatol 2008;48:83-90. 
[88] Klein NP, Bouchard MJ, Wang LH, Kobarg C, Schneider RJ. Src kinases 
involved in hepatitis B virus replication. EMBO J 1999;18:5019-27. 
[89] Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, et al. 
Hepatocellular carcinoma with extrahepatic metastasis: Clinical features and 
prognostic factors. Cancer. 
[90] Tanaka S, Arii S. Molecular targeted therapy for hepatocellular carcinoma in 
the current and potential next strategies. J Gastroenterol 46:289-96. 
 
 
